US 2606903A
· Ruskin
· 1952
[cited by applicant]
US 4861783A
· Ackerman et al.
· 1989
[cited by applicant]
US 4968716A
· Markham
· 1990
[cited by applicant]
US 5070085A
· Markham
· 1991
[cited by applicant]
US 5238683A
· Crystal
· 1993
[cited by applicant]
US 5304724A
· Newton
· 1994
[cited by applicant]
US 5626883A
· Paul
· 1997
[cited by applicant]
US 5824693A
· Goldberg
· 1998
[cited by applicant]
US 5829449A
· Hersh et al.
· 1998
[cited by applicant]
US 5989521A
· Crystal
· 1999
[cited by applicant]
US 6159500A
· Demopoulos et al.
· 2000
[cited by applicant]
US 6228347B1
· Hersh
· 2001
[cited by applicant]
US 6312734B1
· Kozhemyakin et al.
· 2001
[cited by applicant]
US 6350467B1
· Demopoulos et al.
· 2002
[cited by applicant]
US 6423687B1
· Demopoulos et al.
· 2002
[cited by applicant]
US 6601580B1
· Bloch
· 2003
[cited by applicant]
US 6723703B2
· Gaston et al.
· 2004
[cited by applicant]
US 6764693B1
· Smith
· 2004
[cited by applicant]
US 7026342B2
· Wagle et al.
· 2006
[cited by applicant]
US 7384976B2
· Garvey
· 2008
[cited by applicant]
US 9308234B2
· Arnold et al.
· 2016
[cited by applicant]
US 20020037855A1
· Stanislaus
· 2002
[cited by applicant]
US 20020165207A1
· Rosenbloom
· 2002
[cited by applicant]
US 20020179103A1
· Hersh et al.
· 2002
[cited by applicant]
US 20030119909A1
· Stanislaus
· 2003
[cited by applicant]
US 20040071770A1
· Smith
· 2004
[cited by applicant]
US 20040229815A1
· Nagasawa et al.
· 2004
[cited by applicant]
US 20060258599A1
· Childers
· 2006
[cited by applicant]
US 20070049641A1
· Tirouvanziam et al.
· 2007
[cited by applicant]
US 20080008694A1
· Elgebaly et al.
· 2008
[cited by applicant]
US 20090270310A1
· Whyte
· 2009
[cited by applicant]
US 20100310541A1
· Kessler et al.
· 2010
[cited by applicant]
US 20120093947A1
· Britigan et al.
· 2012
[cited by applicant]
US 20130084336A1
· Friedman et al.
· 2013
[cited by applicant]
US 20130129815A1
· Guilford et al.
· 2013
[cited by applicant]
US 20160367620A1
· Demopoulos
· 2016
[cited by applicant]
US 20190231686A1
· Burch
· 2019
[cited by applicant]
US 20220000966A1
· Hoag et al.
· 2022
[cited by applicant]
AU 2004315267A1
· 2005
[cited by applicant]
AU 2004315267B2
· 2009
[cited by applicant]
AU 2005305456B2
· 2011
[cited by applicant]
CA 2058793A1
· 1992
[cited by applicant]
CA 2339473A1
· 2000
[cited by applicant]
CA 2620123A1
· 2007
[cited by applicant]
CA 2620123C
· 2011
[cited by applicant]
CN 1921876A
· 2007
[cited by applicant]
CN 101175499B
· 2010
[cited by applicant]
CN 101987195A
· 2011
[cited by applicant]
CN 102100904B
· 2013
[cited by applicant]
CN 102329370B
· 2015
[cited by applicant]
DE 19935763A1
· 2001
[cited by applicant]
DE 102004035113A1
· 2006
[cited by applicant]
EP 0938331B1
· 2002
[cited by applicant]
EP 1282416A2
· 2003
[cited by applicant]
EP 1701732A2
· 2006
[cited by applicant]
EP 1474158B1
· 2009
[cited by applicant]
EP 1333823B1
· 2010
[cited by applicant]
JP 2004514650A
· 2004
[cited by applicant]
JP 4652664B2
· 2011
[cited by applicant]
WO WO9819694A1
· 1998
[cited by applicant]
WO WO99000106A1
· 1999
[cited by applicant]
WO WO2001002004A1
· 2001
[cited by applicant]
WO WO01089520A2
· 2001
[cited by applicant]
WO WO01089520A3
· 2001
[cited by applicant]
WO WO0232418A1
· 2002
[cited by applicant]
WO WO2002091866A1
· 2002
[cited by applicant]
WO WO2005074903A2
· 2005
[cited by applicant]
WO WO2005074903A3
· 2005
[cited by applicant]
WO WO2005120457A1
· 2005
[cited by applicant]
WO WO2006054304A2
· 2006
[cited by applicant]
WO WO2006060120A2
· 2006
[cited by applicant]
WO WO2006060120A3
· 2006
[cited by applicant]
WO WO2007024876A2
· 2007
[cited by applicant]
WO WO2007024876A3
· 2007
[cited by applicant]
WO WO2007134180A2
· 2007
[cited by applicant]
WO WO2009001884A1
· 2008
[cited by applicant]
WO WO2009069291A1
· 2009
[cited by applicant]
WO WO2010033292A2
· 2010
[cited by applicant]
WO WO2010086530A1
· 2010
[cited by applicant]
WO WO2010131038A2
· 2010
[cited by applicant]
WO WO2012017367A1
· 2012
[cited by applicant]
WO WO2012027603A2
· 2012
[cited by applicant]
WO WO2012085582A1
· 2012
[cited by applicant]
WO WO2014070769A1
· 2014
[cited by applicant]
WO WO2014127245A1
· 2014
[cited by applicant]
WO WO2014132123A2
· 2014
[cited by applicant]
WO WO2016037166A1
· 2016
[cited by applicant]
WO WO2016067283A1
· 2016
[cited by applicant]
WO WO2016088116A1
· 2016
[cited by applicant]
WO WO2018094278A1
· 2018
[cited by applicant]
WO WO2019099946A1
· 2019
[cited by applicant]
WO WO2020211653A1
· 2020
[cited by applicant]
WO WO2024016019A1
· 2024
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/010081, mailed on Jun. 23, 2023, 10 pages.
[cited by applicant]
Wullandri, P., et al., “Application of Modified Atmosphere Packaging (Map) on Fresh Fish,” Squalen. 7(1): 39-49, Kementerian Kelautan dan Perikanan, Indonesia (May 2012).
[cited by applicant]
Adewale, A,T., et al., “Novel Therapy of Bicarbonate, Glutathione, and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport,” American Journal of Respiratory Cell and Molecular Biology 63(3):362-373, American Thoracic…
[cited by applicant]
PubChem SID 439252008, create date, Dec. 19, 2020, p. 2 formula.
[cited by applicant]
Behr, J., et al., “Evidence for Oxidative Stress in Bronchiolitis Obliterans Syndrome After Lung and Heart-lung Transplantation. The Munich Lung Transplant Group,” Transplantation 69(9):1856-1860, Lippincott Williams & …
[cited by applicant]
Borok, MD,Z., et al., “Effect of Glutathione Aerosol on Oxidant-antioxidant Imbalance in Idiopathic Pulmonary Fibrosis,” The Lancet 338(8761):215-216, (Jun. 1991).
[cited by applicant]
Donaldson, S,H., et al., “Mucus Clearance and Lung Function in Cystic Fibrosis With Hypertonic Saline,” The New England Journal of Medicine 354(3):241-250, Boston, United States (Jan. 2006).
[cited by applicant]
Elferink, J,G., et al., “Glutathione-induced Enhancement of Neutrophil Locomotion,” Immunobiology 184(1):25-36, Elsevier, United Kingdom (Dec. 1991).
[cited by applicant]
Henke, M,O., and Ratjen, F., “Mucolytics in Cystic Fibrosis,” Paediatric Respiratory Reviews 8(1):24-29, W.B. Saunders, United Kingdom (Mar. 2007).
[cited by applicant]
Meldrum, W,O., et al., “Mucin Gel Assembly is Controlled by a Collective Action of Non-mucin Proteins, Disulfide Bridges, Ca2+-mediated Links, and Hydrogen Bonding,” Scientific Reports 8(1), (Apr. 2018).
[cited by applicant]
Ramsey, K,A., et al., “Airway Mucus Hyperconcentration in Non-cystic Fibrosis Bronchiectasis,” American Journal of Respiratory and Critical Care Medicine 201(6):661-670, American Thoracic Society, United States (Mar. 20…
[cited by applicant]
Yang, C., et al., “Dornase Alfa for Cystic Fibrosis,” The Cochrane Database of Systematic Reviews 4:CD001127, Wiley, United Kingdom (Apr. 2016).
[cited by applicant]
Avgeri, S.G., et al., “Therapeutic Options for Burkholderia Cepacia Infections Beyond Co-trimoxazole: a Systematic Review of the Clinical Evidence,” International Journal of Antimicrobial Agents 33(5):394-404, Elsevier …
[cited by applicant]
Bishop, C., et al., “A Pilot Study of the Effect of Inhaled Buffered Reduced Glutathione on the Clinical Status of Patients with Cystic Fibrosis,” Chest Journal 127 (1):308-317, Elsevier, Netherlands (Jan. 2005).
[cited by applicant]
Bjarnsholt, T., “The role of bacterial biofilms in chronic infections,” 136:1-51, APMIS Suppl., Blackwell Publishing Ltd., United States (May 2013).
[cited by applicant]
Boies, et al., “Fundamentals of Otolaryngology,” W. B. Saunders Co., Philadelphia, 1989, pp. 184.
[cited by applicant]
Boyanova, et al., “Coadministration of probiotics with antibiotics: why, when and for how long?,” Expert Rev Anti Infect Ther 10(4):407-409, Taylor & Francis, United States (2014).
[cited by applicant]
Bray, T.M., and Taylor, C.G., “Tissue Glutathione, Nutrition, and Oxidative Stress,” Canadian Journal of Physiology and Pharmacology 71(9):746-751, Canadian Science Publishing, Canada (Sep. 1993).
[cited by applicant]
Cursino, L., et al., “Synergic interaction between ascorbic acid and antibiotics against Pseudomonas aeruginosa,” Brazilian Archives of Biology and Technology 48(3): 379-384, Brazilian Archives of Biology and Technology…
[cited by applicant]
Donnelly, L.E., et al., “Defective Phagocytosis in Airways Disease,” Chest 141(4):1055-1062, Elsevier, Netherlands (Apr. 2012).
[cited by applicant]
Fitzpatrick, A.M., et al., “Glutathione oxidation is associated with airway macrophage functional impairment in children with severe asthma,” Pediatric Res 69(2):154-159, International Pediatric Research Foundation Inc.…
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/061686, mailed on Jan. 25, 2019, 8 pages.
[cited by applicant]
Klockgether, J., et al., “Genome Diversity of Pseudomonas Aeruginosa PAO1 Laboratory Strains,” Journal of Bacteriology, 192(4):1113-1121, American Society for Microbiology, United States (Feb. 2010).
[cited by applicant]
Sánchez, C. et al., “Inter-Subject Variability in Human Atrial Action Potential in Sinus Rhythm versus Chronic Atrial Fibrillation,” PLOS One 9(8):e105897, Public Library of Science, United States (Aug. 2014).
[cited by applicant]
Sass, A.M., et al., “The Unexpected Discovery of a Novel Low-oxygen-activated Locus for the Anoxic Persistence of Burkholderia Cenocepacia,” The ISME Journal 7(8):1568-1581, Nature Publishing Group, England (Aug. 2013).
[cited by applicant]
Schwab, U., et al., “Localization of Burkholderia Cepacia Complex Bacteria in Cystic Fibrosis Lungs and Interactions With Pseudomonas Aeruginosa in Hypoxic Mucus,” Infection and immunity 82(11):4729-4745, American Socie…
[cited by applicant]
Shields, R.K., et al., “
[cited by applicant]
Simpson, G.LW., and Ortwerth, B.J., “The Non-Oxidative Degradation of Ascorbic Acid at Physiological Conditions,” Biochimica et Biophysica Acta, 1501(1): 12-24, Elsevier Pub. Co, Netherlands (Apr. 2000).
[cited by applicant]
Taglietti, A., et al., “Antibacterial Activity of Glutathione-Coated Silver Nanoparticles against Gram Positive and Gram Negative Bacteria,” Langmuir, 28(21):8140-8148, American Chemical Society, United States (May 2012…
[cited by applicant]
Tong, S.Y.C., et al., “
[cited by applicant]
Varga, J.J., et al., “Genotypic and Phenotypic Analyses of a Pseudomonas Aeruginosa Chronic Bronchiectasis Isolate Reveal Differences From Cystic Fibrosis and Laboratory Strains,” BMC Genomics 16:883, BioMed Central, En…
[cited by applicant]
Visca, A., et al., “Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study,” Journal of Cystic Fibrosis 7:433-436, Elsevier, Netherlands (Sep. 2008).
[cited by applicant]
Wagner, T., et al., “Effects of Azithromycin on Clinical Isolates of Pseudomonas Aeruginosa From Cystic Fibrosis Patients,” Chest 128(2):912-919, Elsevier Ltd., United States (Aug. 2005).
[cited by applicant]
Zhang, Y and Duan, K., “Glutathione Exhibits Antibacterial Activity and Increases Tetracycline Efficacy against Pseudomonas Aeruginosa,” Science China Life Sciences, 52(6):501-505, Science in China Press, co published w…
[cited by applicant]
Zhao, J., et al., “Decade-long Bacterial Community Dynamics in Cystic Fibrosis Airways,” Proceedings of the National Academy of Sciences of the United States of America 109(15):5809-5814, National Academy of Sciences, U…
[cited by applicant]
Atkuri et al., “N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency” Current Opinion in Pharmacology 7(4):355-359, Elsevier BV, Netherlands (Aug. 2007).
[cited by applicant]
Bergamini et al., “Azithromycin Decreases Glutathione-S-Transferase T1 (GSTT1) and M1 (GSTM1) Expression and Activity in Cystic Fibrosis Airway Epithelial Cells” Pediatric Pulmonology 42(Suppl. 30):297 Abstract 269 (200…
[cited by applicant]
Bergamini et al., “Effects of Azithromycin on Glutathione S-Transferases in Cystic Fibrosis Airway Cells” American Journal of Respiratory Cell and Molecular Biology 41(2):199-206 (Aug. 2009).
[cited by applicant]
Brechbuhl et al., “Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2” Journal of Biological Chemistry 285(22):16582-16587 (May 2010).
[cited by applicant]
Cantin, A.M., “Potential for antioxidant therapy of cystic fibrosis” Current Opinion in Pulmonary Medicine 10(6):531-536, Lippincott Williams and Wilkins Ltd., United States (Nov. 2004).
[cited by applicant]
Caraher, E.M., et al., “The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms” J…
[cited by applicant]
Carter, C.J., “Pathogen and autoantigen homologous regions within the cystic fibrosis transmembrane conductance regulator (CFTR) protein suggest an autoimmune treatable component of cystic fibrosis” FEMS Immunology and …
[cited by applicant]
Cheluvappa et al., “Reactions of Pseudomonas aeruginosa pyocyanin with reduced glutathione,” Acta Biochimica Polonica 55(3):571-580, Frontiers Media SA, Poland (2008).
[cited by applicant]
Cheng, S., et al., “The PDZ domain protein CAL interacts with mGluR5a and modulates receptor expression” Journal of Neurochemistry 112(3):588-598, Wiley-Blackwell Publishing Ltd., United Kingdom (Feb. 2010).
[cited by applicant]
Childers, M., et al., “A new model of cystic fibrosis pathology: Lack of transport of glutathione and its thiocyanate conjugates” Medical Hypotheses 68(1):101-112, Churchill Livingstone, United States (2007).
[cited by applicant]
Ciofu, O., et al., “Respiratory bacterial infections in cystic fibrosis,” Current Opinion in Pulmonary Medicine 19(3):251-258, Lippincott Williams and Wilkins Ltd., United States (May 2013).
[cited by applicant]
Clunes, M.T., et al., “Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder,” Drug Discovery Today 4(2):63-72, Elsevier Ltd., United Kingdom (2007).
[cited by applicant]
Colombo, J.L., “Long-acting bronchodilators in cystic fibrosis,” Curr Opin Pulm Med 9(6):504-508, Lippincott Williams and Wilkins Ltd., United States (Nov. 2003).
[cited by applicant]
Conner, G.E., et al., “The lactoperoxidase system links anion transport to host defense in cystic fibrosis” FEBS Lett 581(2):271-278, Wiley-Blackwell, United States (Jan. 2007).
[cited by applicant]
Dauletbaev, N., et al., “A Phase II Study on Safety and Efficacy of High-Dose N-Acetylcysteine in Patients with Cystic Fibrosis,” Eur J Med Res 14(8):352-358, BioMed Central Ltd., United Kingdom (Aug. 2009).
[cited by applicant]
Day, B.J., et al., “Role for Cystic Fibrosis Transmembrane Conductance Regulator Protein in a Glutathione Response to Bronchopulmonary Pseudomonas Infection,” Infect Immun 72(4):2045-2051, American Society for Microbiol…
[cited by applicant]
Day, Brian J. “Glutathione-A Radical Treatment for Cystic Fibrosis Lung Disease?” Chest 127(1):12-14, American College of Chest Physicians, United States (Jan. 2005).
[cited by applicant]
Donnelly, L.E., et al., “Defective Phagocytosis in Airways Disease,” Chest 141(4):1055-1062, American College of Chest Physicians, United States (Apr. 2012).
[cited by applicant]
D'Orazio, M., et al., “Extracellular Glutathione Decreases the Ability of Burkholderia cenocepacia to Penetrate into Epithelial Cells and to Induce an Inflammatory Response,” PLOS One 7(10):e47550, Public Library of Sci…
[cited by applicant]
Elsheikh, A., et al., “Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis,” J Allergy Clin Immunol 127(6):15431551.e3, Mosby Inc., United States (Jun. …
[cited by applicant]
England, R.J., et al., “Nasal pH measurement: a reliable and repeatable parameter,” Clin Otolaryngol Allied Sci 24(1):67-68, Wiley, United States (Feb. 1999).
[cited by applicant]
Feuillet-Fieux, M.N., et al., “Glutathione S-transferases Related to P. aeruginosa Lung Infection in Cystic Fibrosis Children: Preliminary Study,” Clinical Biochemistry 42(1-2):57-63 Elsevier Inc., United States (Jan. 2…
[cited by applicant]
Fischer, H., “Mechanisms and Function of DUOX in Epithelia of the Lung,” Antioxid Redox Signal 11(10):2453-2465, Mary Ann Liebert Inc., United States (Oct. 2009).
[cited by applicant]
Fisher, A.J., and Pas, R.H.T., “Clinical evaluation of ascoxal a new mucolytic agent,” Anesth Analg 45(5):531-534, Lippincott Williams and Wilkins Ltd., United States (Sep.-Oct. 1966).
[cited by applicant]
Flamant, C., et al., “Glutathione-S-transferase M1 M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis,” Pharmacogenetics 14(5):295-301, Lippincott Williams and Wilkins Ltd., United…
[cited by applicant]
Gao, L., et al., “Abnormal glutathione transport in cystic fibrosis airway epithelia,” Am J Physiol 277(1):L113-L118, American Physiological Society, United States (Jul. 1999).
[cited by applicant]
Gao, L., et al., “Synthetic chloride channel restores glutathione secretion in cystic fibrosis airway epithelia,” Am J Physiol Lung Cell Mol Physiol 281(1):L24-L30, American Physiological Society, United States (Jul. 20…
[cited by applicant]
Geller, D.E., “Aerosol Antibiotics in Cystic Fibrosis,” Respir Care 54(5):658-670, Daedalus Enterprises Inc., United States (May 2009).
[cited by applicant]
Gerson, C., et al., “The Lactoperoxidase System Functions in Bacterial Clearance of Airways,” Am J Respir Cell Mol Biol 22:665-671, American Thoracic Society, United States (Jun. 2000).
[cited by applicant]
Gould, N., and Day, B.J., “Targeting maladaptive glutathione responses in lung disease,” Biochemical Pharmacology 81(2):187-193, Elsevier Inc., United States (Jan. 2011).
[cited by applicant]
Govindaraju, K., et al., “Analysis of Glutathione in Rat Airway Surface Liquid by Capillary Zone Electrophoresis with Conductivity Detection,” Journal of Chromatography B-Analytical Technologies in the Biomedical and Li…
[cited by applicant]
Griese, M., et al., “Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis,” Am J Respir Crit Care Med 169(7):822-828, American Thoracic Society, United States (Apr. 2004).
[cited by applicant]
Griese, M., et al., “Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis,” Am J Respir Crit Care Med 188(1):83-89, American Thoracic Society, United States (Jul. 2013).
[cited by applicant]
Grigoras, I., et al., “Functional Characterization of the
[cited by applicant]
Gukasyan, H.J., et al., “Glutathione and its transporters in ocular surface defense,” Ocul Surf 5(4):269-279, Elsevier Inc., United States (Oct. 2007).
[cited by applicant]
Hartl D., et al., “Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs,” Free Radic Biol Med 39(4):463-472, Elsevier Inc., United States (Aug. 2005).
[cited by applicant]
Wood, L.G., et al., “Biomarkers of lipid peroxidation, airway inflammation and asthma,” Eur Respir J 21(1):177-186, European Respiratory Society, Switzerland (Jan. 2003).
[cited by applicant]
Hector et al., “Glutathione in Airway Neutrophils in Cystic Fibrosis,” Pediatric Pulmonology 44(Suppl. 32) Abstract 420:359-360 (2009).
[cited by applicant]
Hector, A., et al., “Novel Method to Process Cystic Fibrosis Sputum for Determination of Oxidative State,” Respiration 80(5):393-400 S. Karger AG, Switzerland (2010).
[cited by applicant]
Henrion-Caude, A., et al., “Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism,” Hepatology 36(4):913-917, John Wiley and Sons Ltd., United States (Oct.…
[cited by applicant]
Howell, L.D., et al., “ATP hydrolysis by a CFTR domain: Pharmacology and effects of G551D mutation,” Biochem Biophys Res Commun 271(2):518-525, Academic Press Inc., United States (May 2000).
[cited by applicant]
Huang, Y.J., et al., “Airway Microbiota and Bronchial Hyperresponsiveness in Patients with Suboptimally Controlled Asthma,” J Allergy Clin Immunol 127(2):372-381.e3, Mosby Inc., United States (Feb. 2011).
[cited by applicant]
Hudson, V.M., Valerie “Differing Compartments of Intracellular Glutathione Have Differing Levels of Glutathione in Cystic Fibrosis,” Med Hypotheses 68(4):919-920, Churchill Livingstone, United States (2007).
[cited by applicant]
Hudson, V.M., “Rethinking cystic fibrosis pathology: The critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation,” Free Radic Biol Med 30(12):1440-1461, Elsevier Inc., United States (Jun. 2…
[cited by applicant]
Inci, I., et al., “Prevention of primary graft dysfunction in lung transplantation by N-acetylcysteine after prolonged cold ischemia,” J Heart Lung Transplant 29(11):1293-1301, Elseveir USA, United States (Nov. 2010).
[cited by applicant]
Innis, S.M., et al., “Choline-related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis,” Am J Clin Nutr 85(3):702-708, American Society for …
[cited by applicant]
Lehr “Global Markets for Asthma and COPD Drugs,” BCC Research Market Forecasting 1-159 (2012).
[cited by applicant]
Nagavarapu “Pulmonary Drug Delivery Systems: Technologies and Global Markets,” BCC Research Market Forecasting:1-222 (2012).
[cited by applicant]
Jungas, T., et al., “Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator,” J Biol Chem 277(31):2791…
[cited by applicant]
Kariya, C., et al., “A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration,” Am J Physiol Lung Cell Mol Physiol 292(6):L1590-L1597, American Physiological Society, United …
[cited by applicant]
Kogan, I., et al., “CFTR directly mediates nucleotide-regulated glutathione flux,” EMBO J 22(9):1981-1989, Wiley-Blackwell, Germany (May 2003).
[cited by applicant]
Korytina, G.F., et al., “Polymorphism of glutathione S-transferase M1 and P1 in patients with cystic fibrosis and chronic respiratory diseases,” Russian Journal of Genetics 40(3):314-320 (Mar. 2004).
[cited by applicant]
Lands, L.C., et al., “Lymphocyte Glutathione Levels in Children with Cystic Fibrosis,” Chest 116:201-205, American College of Chest Physicians, United States (Jul. 1999).
[cited by applicant]
Lands, L.C., et al., “Total Plasma Antioxidant Capacity in Cystic Fibrosis,” Pediatric Pulmonology 29(2):81-87, Wiley-Liss Inc., United States (Feb. 2000).
[cited by applicant]
Lands, L.C. “Nutrition in pediatric lung disease,” Paediatric Respir Rev 8(4):305-312 (Dec. 2007).
[cited by applicant]
Laskowska-Klita, T., et al., “Antioxidant status in erythrocytes of cystic fibrosis children,” Acta Biochimica Polonica 48(1):283-285, Acta Biochimica Polonica, Poland (2001).
[cited by applicant]
Lasry, A., et al., “Inflammatory networks underlying colorectal cancer,” Nat Immunol, 17(3)230-240, Nature Publishing Group, United Kingdom (Mar. 2016).
[cited by applicant]
Li, C., et al., “Spatiotemporal Coupling of CAMP Transporter to CFTR Chloride Channel Function in the Gut Epithelia,” Cell 131(5):940-951, Cell Press, United States (Nov. 2007).
[cited by applicant]
Lima, C., et al., “Cystic fibrosis transmembrane conductance regulator gene mutations and glutathione S-transferase null genotypes in cystic fibrosis patients in Brazil,” J Bras Pneumol 38(1):50-56, Sociedade Brasileira…
[cited by applicant]
Lothian, J.B., et al., “Effect of whey protein to modulate immune response in children with atopic asthma,” Int J Food Sci Nutr 57(3-4):204-211, Informa Healthcare, United Kingdom (May-Jun. 2006).
[cited by applicant]
Madarasi, A., et al., “Antioxidant Status in Patients with Cystic Fibrosis,” Ann Nutr Metab 44(5-6):207-211, S. Karger AG, Switzerland (2000).
[cited by applicant]
Martin, C., et al., “Host-microbe interactions in distal airways: relevance to chronic airway diseases,” Eur Respir Rev 24(135):78-91, European Respiratory Society, Switzerland (Mar. 2015).
[cited by applicant]
McKone, E.F., et al., “Variants in the Glutamate-Cysteine-Ligase Gene Are Associated with Cystic Fibrosis Lung Disease,” Am J Respir Crit Care Med 174(4):415-419, American Thoracic Society, United States (Aug. 2006).
[cited by applicant]
Moskwa, P., et al., “A Novel Host Defense System of Airways is Defective in Cystic Fibrosis,” Am J Respir Crit Care Med 175(2):174-183, American Thoracic Society, United States (Jan. 2007).
[cited by applicant]
Murphy, T.F. “The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease,” Curr Opin Infect Dis 19(3):225-230, Lippincott Williams and Wilkins Ltd., United States (Jun. 2006).
[cited by applicant]
None, L.V., et al., “Residual Gravimetric Method to Measure Nebulizer Output,” J Aerosol Med 17(1):63-72, Mary Ann Liebert, United States (2004).
[cited by applicant]
O'Brien, P.J., “Peroxidases,” Chem Biol Interact 129(1-2):113-139, Elsevier Ireland Ltd., Ireland (Dec. 2000).
[cited by applicant]
Perez-Vilar, J., and Boucher, R.C., “Reevaluating Gel-Forming Mucins' Roles in Cystic Fibrosis Lung Disease,” Free Radic Biol Med 37(10):1564-1577, Elsevier Inc., United States (Nov. 2004).
[cited by applicant]
Pitt, B.R. “CFTR trafficking and signaling in respiratory epithelium,” Am J Physiol Lung Cell Mol Physiol 281(1):L13-L15, American Physiological Society, United States (Jul. 2001).
[cited by applicant]
Prousky, J., “The Treatment of Pulmonary Diseases and Respiratory-Related Conditions with inhaled (Nebulized or Aerosolized) Glutathione,” Evid Based Complement Alternat Med 5(1):27-35, Hindawi Publishing Corporation, U…
[cited by applicant]
Rada, B., “The Pseudomonas Toxin Pyocyanin Inhibits the Dual Oxidase-Based Antimicrobial System as It Imposes Oxidative Stress on Airway Epithelial Cells,” J Immunol 181(7):4883-4893, American Association of Immunologis…
[cited by applicant]
Remund, K.F., et al., “Infections Relevant to Lung Transplantation,” Proc Am Thorac Soc 6(1):94-100 (Jan. 2009).
[cited by applicant]
Rogan, M.P., et al., “Loss of Microbicidal Activity and increased Formation of Biofilm Due to Decreased Lactoferrin Activity in Patients with Cystic Fibrosis,” J Infect Dis 190(7):1245-1253, Oxford University Press, Uni…
[cited by applicant]
Roux et al., “
[cited by applicant]
Schwarzer, C., et al., “Organelle redox of CF and CFTR-corrected airway epithelia,” Free Radic Biol Med 43(2):300-316, Elsevier Inc., United States (Jul. 2007).
[cited by applicant]
Schwarzer, C., et al., “Oxidative Stress Caused by Pyocyanin Impairs CFTR C1-Transport in Human Bronchial Epithelial Cells,” Free Radic Biol Med 45(12):1653-1662, Elsevier Inc., United States (Dec. 2008).
[cited by applicant]
Šidlová, K., et al., “Serum alpha-glutathione S-transferase as a sensitive marker of hepatocellular damage in patients with cystic fibrosis,” Physiol Res 52(3):361-365,Czech Academy of Sciences, Czech Republic (2003).
[cited by applicant]
Snyder, A.H., et al., “Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis,” Am J Respir Crit Care Med 165(7):922-926, American Thoracic Society, United States (Apr. 2002).
[cited by applicant]
Sonni, F., et al., “Antioxidant Action of Glutathione and the Ascorbic Acid/Glutathione Pair in a Model White Wine,” J Agric Food Chem 59(8):3940-3949, American Chemical Society, United States (Apr. 2011).
[cited by applicant]
Speich, R., and Van Der Bij, W., “Epidemiology and Management of Infections after Lung Transplantation,” Clin Infect Dis 33(Suppl 1):S58-S65, Oxford University Press, United Kingdom (Jul. 2001).
[cited by applicant]
Szentpétery, Z., et al., “Functional Studies on the MRP1 Multidrug Transporter: Characterization of ABC-Signature Mutant Variants,” Anticancer Res 24(2A):449-455, International Institute of Anticancer Research, Greece (…
[cited by applicant]
Thomas, E.L., and Aune, T.M., et al., “Lactoperoxidase, peroxide, thiocyanate antimicrobial system: correlation of sulfhydryl oxidation with antimicrobial action,” Infect Immun 20(2):456-483, American Society for Microb…
[cited by applicant]
Thome, U., et al., “Novel SIN-1 Reactive Intermediates Modulate Chloride Secretion Across Murine Airway Cells,” Free Radic Biol Med 35(6):662-675, Elsevier Inc., United States (Sep. 2003).
[cited by applicant]
Tirouvanziam, R., et al., “High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis,” Proc Natl Acad Sci USA 103(12):4628-4633, National Academy of Sciences, United States (Mar. …
[cited by applicant]
Tournoud, M., et al., “Structural equations to model relationships between pulmonary function, fatty acids and oxidation in cystic fibrosis,” Scand J Clin Lab Invest 69(1):36-44, Informa Healthcare, United Kingdom (2009…
[cited by applicant]
Vasu, V.T., et al., “Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase,” Free Radic Res 45(2):165-176, Elsevier Inc., United States (Feb. 2011).
[cited by applicant]
Velsor, L.W., et al., “Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice,” Am J Physiol Lung Cell Mol Physiol 281(1):L31-L38, American Physiological Society, U…
[cited by applicant]
Venglarik, C.J., et al., “Hypochlorous acid alters bronchial epithelial cell membrane properties and prevention by extracellular glutathione,” J Appl Physiol 95(6):2444-2452, American Physiological Society, United State…
[cited by applicant]
Vilela, R.M., et al., “High hydrostatic pressure enhances whey protein digestibility to generate whey peptides that improve glutathione status in CFTR-deficient lung epithelial cells,” Mol Nutr Food Res 50(11):1013-1029…
[cited by applicant]
Vilela, R.M., et al., “Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide,” Int Immunopharmacol 6(11):1651-1664, Elsevier, Netherlands (Nov. 2006).
[cited by applicant]
Visca, A., et al., “Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study,” J Cyst Fibros 7(5):433-436, Elsevier, Netherlands (Sep. 2008).
[cited by applicant]
Wang, W., et al., “Reversible silencing of CFTR chloride channels by glutathionylation,” J Gen Physiol 125(2):127-141, Rockefeller University Press, United States (Feb. 2005).
[cited by applicant]
Ward, P.P., et al., “Lactoferrin and host defense,” Biochem Cell Biol 80(1):95-102, National Research Council of Canada, Canada (2002).
[cited by applicant]
Willing et al., “Shifting the balance: antibiotic effects on host-microbiota mutualism,” Nature Reviews Microbiology 9(4):233-243 (2011) (Abstract Only).
[cited by applicant]
Dewan “Advanced Drug Delivery Systems: Technologies and Global Markets,” BCC Research Market Forecasting:1-278 (2011).
[cited by applicant]
Dewan “Global Markets for Orphan Drugs” BCC Research Market Forecasting: 1-212 (2013).
[cited by applicant]
Highsmith “Biologic Therapeutic Drugs: Technologies and Global Markets,” BCC Research Market Forecasting: 1-168 (2013).
[cited by applicant]
Hancock, R.E.W., and Wong, P.G.W., “Compounds Which Increase the Permeability of the Pseudomonas aeruginosa Outer Membrane,” Antimicrobial Agents and Chemotherapy, 26(1): 48-52, American Society for Microbiology, United…
[cited by applicant]
Hubert, D., et al., “Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments,” European Respiratory Journal, 34: 117-124, ERS Journal Ltd., Switzerland (Jul. 2009).
[cited by applicant]
Fischer, H., et al., “Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel,” PNAS, 101(10): 3691-3696, The National Academy of Science of the USA, United States (Mar. 2004).
[cited by applicant]
Fischer, H., and Widdicombe, J.H., Mechanisms of Acid and Base Secretion by the Airway Epithelium, J Membr Biol 211(3): 139-150, Springer Science, Germany (2006).
[cited by applicant]
Fisher, A. J., et al., “Cross sectional study of exhaled nitric oxide levels following lung transplantation,” Thorax 53(6):454-458, British Thoracic Society, United Kingdom (Jun. 1998).
[cited by applicant]
Jiao, J., et al., “The effects of vitamins C and B12 on human nasal ciliary beat frequency,” BMC Complementary and Alternative Medicine 13(110): 1-6, Springer Nature, Berlin (May 2013).
[cited by applicant]
Griese, M., et al., “Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis,” Am J Respir Crit Care Med 188(1): 83-89, The American Thoracic Society, United States (Jul. 2013).
[cited by applicant]
Birket, S.E., et all., “A Functional Anatomic Defect of the Cystic Fibrosis Airway,” Am J Respir Crit Care Med 190(4): 421-432, The American Thoracic Society, United States (Aug. 2014).
[cited by applicant]
Liu, L., et al., “Method for Quantitative Study of Airway Functional Microanatomy Using Micro-Optical Coherence Tomography,” PLOS One 8(1): e54473, Public Library of Science, United States (2013).
[cited by applicant]
Liu, L., et al., “An Autoregulatory Mechanism Governing Mucociliary Transport Is Sensitive to Mucus Load,” Am J Prespir Cell Mol Biol 51(4):485-93, The American Thoracic Society, United States (Oct. 2014).
[cited by applicant]
Gabbay, E., et al., “Post-lung Transplant Bronchiolitis Obliterans Syndrome (BOS) Is Characterized by Increase exhaled Nitric Oxide Levels and Epithelial Inducible Nitric Oxide Synthase,” Am J Respir Crit Care Med 162(6…
[cited by applicant]
Gaggar, A., et al., “The role of matrix metalloproteases in cystic fibrosis lung disease,” Eur Respir J 38(3):721-727, European Respiratory Society, Switzerland (Sep. 2011).
[cited by applicant]
Martinez-Alemán, S. R., “Understanding the entanglement: Neutrophil Extracellular Traps (NETs) in Cystic Fibrosis,” Front Cell Infect Microbiol 7:104, Frontiers Media S.A., Switzerland (Apr. 2017).
[cited by applicant]
Morice, A.H., “Airway reflux as a cause of respiratory disease,” Breathe, 9(4): 256-266, European Respiratory Society, Switzerland (2013).
[cited by applicant]
Tang, X., et al., “Acidic pH increases airways surface liquid viscosity in cystic fibrosis,” J Clin Invest 126(3):879-891, American Society for Clinical Investigation, United States (Mar. 2016).
[cited by applicant]
Tate, S., et al., “Airways in cystic fibrosis are acidified: detection by exhaled breath condensate,” Thorax 57:926-929, BMJ Publishing Group Ltd & British Thoracic Society, United Kingdom (Nov. 2002).
[cited by applicant]
Francoeur, C., and Denis, M., “Nitric oxide and interleukin-8 as inflammatory components of cystic fibrosis,” Inflammation 19(5):587-598, Springer, Germany (Oct. 1995).
[cited by applicant]
Dickerhof, N., et al., “Oxidative stress in early cystic fibrosis ling disease is exacerbated by airway glutathione deficiency,” Free Radical Biology and Medicine 113: 236-243, Elsevier, Netherlands (Dec. 2017).
[cited by applicant]
Kharitonov, S.A., et al., “Increased nitric oxide in exhaled air of asthmatic patients” The Lancet 343(8890): p. 133-p. 135, Elsevier, Netherlands (Jan. 1994).
[cited by applicant]
Klare, W., et al., “Glutatione-disrupted biofilms of clinical Pseudomonas aeruginosa strains exhibit an enhanced antibiotic effect and a novel biofilm transcriptome,” Antimicrob Agents Chemother 60(8):4539-4551, America…
[cited by applicant]
O'donnell, M.D., et al., “Treatment of Idiopathic Bronchiectasis With Aerosolized Recombinant Human DNase I,” Chest 113(5):1329-1334, Elsevier, Netherlands (May 1998).
[cited by applicant]
Paez, P.L., et al., “Effect of the association of reduced glutathione and ciprofloxacin on the antimicrobial activity in
[cited by applicant]
Rawal, B.D., et al., “Inhibition of Pseudomonas aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies,” Med J Aust 1(6):169-174, John Wiley & Sons, United States …
[cited by applicant]
Sakakura, Y., et al., “Mucociliary Function during experimentally Induced Rhinovirus Infection in Man,” Ann Otol Rhinol Laryngol 82(2):203-211, Sage Publications, United States (Mar.-Apr. 1973).
[cited by applicant]
Vasilenko, A., “Antibacterial activity of glutathione in carbapenemase-producing Klebsiella pneumoniae and Pseudomonas aeruginosa,” a Master's Thesis submitted to the Faculty of Richard L. Conolly College, Long Island U…
[cited by applicant]
WebAssign, “Lab 10—Electrochemical Cells,” General Chemistry II Labs, accessed at www.webassign.net/question_assets/ncsugenchem202labv1/lab_10/manual.html, downloaded on Sep. 2, 2020, 8 pages.
[cited by applicant]
De Villiers, B.L., et al., “Optimizing MCPA (K-salt) activity with adjuvants,” South African Journal of Plant and Soil 17(2):63-65, Taylor and Francis Ltd., United Kingdom (2000).
[cited by applicant]
Pedemonte, N., et al., “Thiocyanate Transport in Resting and IL-4 Stimulated Human Bronchial Epithelial Cells; Role of Pendrin and Anion Channels,” J Immunol 178(8):5144-5153, American Association of Immunologists, Unit…
[cited by applicant]
Aliberti, S., et al., “Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations,” Lancet Respir Med 2600(21):1-…
[cited by applicant]
Chalmers, J. D., and Hill, A. T., “Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis,” Molecular Immunology 55(1):27-34, Elsevier, Netherlands (Aug. 2013).
[cited by applicant]
Chalmers, J. D., et al., “Bronchiectasis,” Nature Reviews Disease Primers 4:45, 18 pages, Nature Publishing Group, United Kingdom (Nov. 2018).
[cited by applicant]
King, P. T., “The pathophysiology of bronchiectasis,” Int J Chron Obstruct Pulmon Dis 4:411-419, Dove Press, New Zealand (Nov. 2009).
[cited by applicant]
Nosotti, M., et al., “Infections after lung transplantation,” Journal of Thoracic Disease 10(6):3849-3868, Pioneer Bioscience Publishing Company, Hong Kong (Jun. 2018).
[cited by applicant]
Okamoto, K., and Santos, C. A. Q., “Management and prophylaxis of bacterial and mycobacterial infections among lung transplant recipients,” Ann Transl Med 8(6):413, 12 pages, AME Publishing Company, China (Mar. 2020).
[cited by applicant]
Schäfer, J., et al., “Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis,” BMC Pulm Med 18(1):79, 11 pages, BioMed Central Ltd., United Kingdom (May 2018).
[cited by applicant]
Fux, C.A., et al., “Can laboratory reference strains mirror ‘real-world’ pathogenesis?,” Trends Microbiol 13(2):58-63, Elsevier, Netherlands (Feb. 2005).
[cited by applicant]
Grosso-Becerra, M-V., et al., “Pseudomonas aeruginosa clinical and environmental isolates constitute a single population with high phenotypic diversity,” BMC Genomics 15(318):1-14, BioMed Central, United Kingdom (Apr. 2…
[cited by applicant]
Hanberger, H., et al., “Antibiotic Susceptibility Among Aerobic Gram-negative Bacilli in Intensive Care Units in 5 European Countries,” JAMA 281 (1):67-71, American Medical Association, United States (Jan. 1999).
[cited by applicant]
Hayes, D., et al., “Lung transplantation for advanced bronchiectasis,” Semin Respir Crit Care Med 31(2):123-38, American Thoracic Society, United States (Apr. 2010).
[cited by applicant]
Visscher, D.W., et al., “Bronchiolitis: the pathologist's perspective,” Proc Am Thorac Soc 3(1):41-47, American Thoracic Society, United States (2006).
[cited by applicant]
Saayman, S., et al., “Cystic Fibrosis Transmembrane Receptor Expression is Regulated by Long Antisense Non-Coding RNAs,” Molecular Therapy 22, Supplement 1:S4, Cell Press, United States (May 2014).
[cited by applicant]
Sodium Bicarbonate, PubChem ID 516892, accessed at https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-bicarbonate, accessed on Oct. 6, 2022.
[cited by applicant]
Ascorbic Acid, PubChem ID 54670067, accessed at https://pubchem.ncbi.nlm.nih.gov/compound/Ascorbic-acid, accessed on Oct. 6, 2022.
[cited by applicant]
Glutathione, PubChem ID 124886, accessed at https://pubchem.ncbi.nlm.nih.gov/compound/Glutathione, accessed on Oct. 6, 2022.
[cited by applicant]
Sass, R.L., and Scheuerman, R.F., “Sodium Bicarbonate, Entry for Nahcolite,” in Handbook of Mineralogy, Mineral Data Publishing, United States (1962).
[cited by applicant]
Notice of Allowance mailed May 28, 2024, in U.S. Appl. No. 18/640,964, Delaney, E., et al., filed Apr. 19, 2024, 8 pages.
[cited by applicant]